Defining the Appropriate Patient Population for Primary Brachytherapy for Localized Prostate Cancer: Work in Progress

Mayo Clinic Proceedings

Volumn 79, Issue 3, 2004, Pages 307-308

  Frank, Igor ^a   Blute, Michael L ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PALLADIUM 103;

BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; MICTURITION DISORDER; MORBIDITY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; URETHRA; URINE FLOW RATE;

EID: 1442355668     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.3.307     Document Type: Editorial

References (11)

1. Wehle MJ, Lisson SW, Buskirk SJ, Broderick GA, Young, PR, Igel TC. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc. 2004;79:314-317.
2. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Measurement Committee of the American Urological Association. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine. Medical Assessment Program symptom indexes. J Urol. 1992;148:1558-1563.
3. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
4. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59-67.
5. Kleinberg L, Wallner K, Roy J, et al. Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys. 1994;28:985-990.
6. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557-566.
7. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465-471.
8. Stokes SH, Real JD, Adams PW, Clements JC, Wuertzer S, Kan W. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;37:337-341.
9. Leibovich BC, Blute ML, Bostwick DG, et al. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000;56:726-729.
10. Thomas MD, Cormack R, Tempany CM, et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:905-908.
11. Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with prostate implant: iodine-125 vs palladium-103. Radiat Oncol Investig. 1999;7:278-288.